Sarepta Therapeutics, Inc. income statement

In fiscal 2025, Sarepta Therapeutics, Inc. reported revenue of $2.20bn, up 15.6% on the year before, operating income of −$700m (a -31.8% margin) and net income of −$713m, or −$7.13 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sarepta Therapeutics, Inc.: income statement, annual
Fiscal year	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	10	1	5	155	301	381	540	702	933	1,243	1,902	2,198	1,974
Cost of revenue	—	—	—	—	—	—	—	—	—	—	—	26	—
Gross profit	—	—	—	—	—	—	—	—	—	—	—	2,173	—
Research and development	94	146	188	167	402	561	722	771	877	877	805	1,522	789
Selling, general and administrative	49	75	84	123	208	285	318	283	451	482	558	492	437
Operating income	−134	−220	−267	−172	−344	−706	−564	−460	−536	−268	218	−700	−143
Interest expense	0	1	2	6	34	31	60	64	−53	−22	−18	−38	−81
Income before tax	—	−220	−267	−49	−363	−714	−553	−419	−690	−520	261	−702	−131
Income tax	—	—	—	2	−1	1	1	−0	14	16	26	11	6
Net income	−136	−220	−267	−51	−362	−715	−554	−419	−703	−536	235	−713	−137
Diluted EPS	−$3.39	−$5.20	−$5.49	−$0.86	−$5.46	−$9.71	−$7.11	−$5.15	−$8.03	−$5.80	$2.34	−$7.13	−$1.29
Diluted shares (average)	40m	42m	49m	59m	66m	74m	78m	81m	88m	92m	108m	100m	106m
EBITDA	−130	−215	−261	−164	−331	−681	−537	−422	−494	−223	256	−655	−99

US$ millions unless shown otherwise. Fiscal quarters.

Sarepta Therapeutics, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	467	658	745	611	399	443	731	401
Gross profit	338	506	474	361	219	−29	—	—
Research and development	224	200	773	204	219	325	154	91
Selling, general and administrative	128	164	134	138	92	128	109	108
Operating income	22	162	−300	116	−103	−412	358	13
Interest expense	5	−32	−5	−5	2	−40	−22	−22
Income before tax	34	172	−384	154	−194	−278	343	−2
Income tax	0	13	64	−43	−14	5	12	3
Net income	34	83	−448	197	−51	−412	331	−5
Diluted EPS	$0.34	$1.50	−$4.60	$1.89	−$0.50	−$3.93	$2.88	−$0.05
EBITDA	32	172	−290	126	−85	−406	369	24

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: MRNA vs SRPT ALKS vs SRPT HALO vs SRPT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Sarepta Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sarepta Therapeutics, Inc.